1190862-16-8Relevant articles and documents
Indolin-2-one p38α inhibitors II: Lead optimisation
Eastwood, Paul,González, Jacob,Gómez, Elena,Caturla, Francisco,Balagué, Cristina,Orellana, Adelina,Domínguez, María
, p. 5270 - 5273 (2011)
Optimisation of a series of indolin-2-one p38α inhibitors was achieved via both blocking of a potential metabolic 'hot spot' and by increasing overall polarity of the lead series leading to non-cytotoxic compounds which showed improved oral bioavailabilities in the rat.
New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
-
Page/Page column 29, (2009/12/04)
This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.